The American Cancer Society National Lung Cancer Roundtable strategic plan: Challenges in clinical guideline recommendations for biomarker testing in lung cancer
Cancer · 15.05.2026 · 132 (10)
DOI: 10.1002/cncr.70384 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Cancer, online erschienen am 12.05.2026. Verfasst von Shetal A Patel und 21 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicine, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, USA. Hauptthemen laut MEDLINE: Lung Neoplasms, Biomarkers, Tumor, Practice Guidelines as Topic, Carcinoma, Non-Small-Cell Lung. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 28 Literaturangaben.
Abstract (Originalsprache)
Molecular profiling has revolutionized the diagnosis and management of patients with non‐small cell lung cancer (NSCLC), enabling personalized treatment approaches that have significantly improved patient outcomes. Identifying specific gene mutations and protein expression profiles guides therapeutic decisions and has become standard in the management of patients with NSCLC. Multiple organizations have published guidelines for biomarker testing. However, differences in the timing, methodology, and scope of recommended targets create potential for inconsistencies in clinical practice. This article reviews the clinical importance of biomarker testing in NSCLC, compares major guidelines, and highlights the challenges and implications of guideline variability in formulating recommendations on biomarker testing for patients with NSCLC.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Medicine, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, USA.
- Lineberger Comprehensive Cancer Center, Chapel Hill, North Carolina, USA.
- Infectious Disease Society of America, Arlington, Virginia, USA.
- Division of Pulmonary and Critical Care Medicine, University of Rochester Medical Center, Rochester, New York, USA.
- Department of Pathology, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, USA.
- The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
ORCID-Profile: Shetal A Patel, Farhood Farjah, Robert A Smith, M Patricia Rivera
Zitieren
APA
Patel, S. A., Heald, J. L., Nead, M., Singer, B., Eapen, G. A., Farjah, F., Kelly, K., Kim, E. S., Mani, H., Osarogiagbon, R. U., Pastis, N. J., Pannu, J. K., Scholl, L., Sears, C. R., Silvestri, G. A., Smith, R. A., Suh, R. D., Wood, D., DiJulio, T. A., …, & Rivera, M. P. (2026). The American Cancer Society National Lung Cancer Roundtable strategic plan: Challenges in clinical guideline recommendations for biomarker testing in lung cancer. Cancer, 132(10). https://doi.org/10.1002/cncr.70384
Vancouver
Patel SA, Heald JL, Nead M, Singer B, Eapen GA, Farjah F, et al. The American Cancer Society National Lung Cancer Roundtable strategic plan: Challenges in clinical guideline recommendations for biomarker testing in lung cancer. Cancer. 2026;132(10). doi:10.1002/cncr.70384
BibTeX
@article{Patel2026,
author = {Patel, Shetal A and Heald, Jonathan L and Nead, Michael and Singer, Bart and Eapen, George A and Farjah, Farhood and Kelly, Karen and Kim, Edward S and Mani, Haresh and Osarogiagbon, Raymond U and Pastis, Nicholas J and Pannu, Jasleen K and Scholl, Lynette and Sears, Catherine R and Silvestri, Gerard A and Smith, Robert A and Suh, Robert D and Wood, Douglas and DiJulio, Terri A and Johnson, Bruce E and Wistuba, Ignacio I and Rivera, M Patricia},
title = {The American Cancer Society National Lung Cancer Roundtable strategic plan: Challenges in clinical guideline recommendations for biomarker testing in lung cancer},
journal = {Cancer},
year = {2026},
volume = {132},
number = {10},
doi = {10.1002/cncr.70384}
}
EUVIMED